Sorum Alexander W, Shrimp Jonathan H, Roberts Allison M, Montgomery David C, Tiwari Neil K, Lal-Nag Madhu, Simeonov Anton, Jadhav Ajit, Meier Jordan L
Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Frederick, Maryland 21702, United States.
Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health , Rockville, Maryland 20850, United States.
ACS Chem Biol. 2016 Mar 18;11(3):734-41. doi: 10.1021/acschembio.5b00709. Epub 2015 Oct 14.
Lysine acetyltransferases (KATs) are critical regulators of signaling in many diseases, including cancer. A major challenge in establishing the targetable functions of KATs in disease is a lack of well-characterized, cell-active KAT inhibitors. To confront this challenge, here we report a microfluidic mobility shift platform for the discovery and characterization of small molecule KAT inhibitors. Novel fluorescent peptide substrates were developed for four well-known KAT enzymes (p300, Crebbp, Morf, and Gcn5). Enzyme-catalyzed acetylation alters the electrophoretic mobility of these peptides in a microfluidic chip, allowing facile and direct monitoring of KAT activity. A pilot screen was used to demonstrate the utility of microfluidic mobility shift profiling to identify known and novel modulators of KAT activity. Real-time kinetic monitoring of KAT activity revealed that garcinol, a natural product KAT inhibitor used in cellular studies, exhibits time-dependent and detergent-sensitive inhibition, consistent with an aggregation-based mechanism. In contrast, the cell-permeable bisubstrate inhibitor Tat-CoA exhibited potent and time-independent KAT inhibition, highlighting its potential utility as a cellular inhibitor of KAT activity. These studies define microfluidic mobility shift profiling as a powerful platform for the discovery and characterization of small molecule inhibitors of KAT activity, and provide mechanistic insights potentially important for the application of KAT inhibitors in cellular contexts.
赖氨酸乙酰转移酶(KATs)是包括癌症在内的多种疾病信号传导的关键调节因子。确定KATs在疾病中的可靶向功能面临的一个主要挑战是缺乏特征明确、具有细胞活性的KAT抑制剂。为应对这一挑战,我们在此报告一种用于发现和表征小分子KAT抑制剂的微流控迁移率偏移平台。针对四种著名的KAT酶(p300、Crebbp、Morf和Gcn5)开发了新型荧光肽底物。酶催化的乙酰化改变了这些肽在微流控芯片中的电泳迁移率,从而能够轻松直接地监测KAT活性。通过初步筛选证明了微流控迁移率偏移分析在鉴定已知和新型KAT活性调节剂方面的实用性。对KAT活性的实时动力学监测表明,用于细胞研究的天然产物KAT抑制剂藤黄酚表现出时间依赖性和去污剂敏感性抑制,这与基于聚集的机制一致。相比之下,细胞可渗透的双底物抑制剂Tat-CoA表现出强效且与时间无关的KAT抑制作用,突出了其作为KAT活性细胞抑制剂的潜在用途。这些研究将微流控迁移率偏移分析定义为发现和表征KAT活性小分子抑制剂的强大平台,并提供了对于KAT抑制剂在细胞环境中的应用可能重要的机制见解。